Biontech is growing: The corona vaccine manufacturer was able to increase its profit again. Other follow-up versions of the previous Covid 19 vaccine are also being tested.
The corona vaccine manufacturer Biontech was again able to significantly increase sales and profits in the first quarter.
In the quarter that ended at the end of March, there was a net profit of around 3.70 billion euros in the books after around 1.13 billion euros in the same period last year, as the company announced on Monday in Mainz. Sales increased from 2.05 billion euros to 6.37 billion euros. When presenting the new figures, Biontech confirmed its sales forecast for its corona vaccine of EUR 13 billion to EUR 17 billion for the current financial year.
According to their own statements, Biontech and its US partner Pfizer are still examining possible successor versions of the previous Covid 19 vaccine. Among other things, this involves a vaccine candidate based on the omicron variant and so-called bivalent vaccines that are directed against omicron and other Sars-CoV-2 strains. An update of the data from the clinical trials that started in January is “expected in the coming weeks and made available to the regulatory authorities,” the company said.
In the past fiscal year, Biontech had generated a net profit of around 10.3 billion euros. Sales were almost 19 billion euros.
Source: Stern
Jane Stock is a technology author, who has written for 24 Hours World. She writes about the latest in technology news and trends, and is always on the lookout for new and innovative ways to improve his audience’s experience.
